FDA Approves Supplemental New Drug Application to Expand Cinvanti (aprepitant) Label for IV Push

Article Link: FDA Approves Supplemental New Drug Application to Expand Cinvanti (aprepitant) Label for IV Push

SAN DIEGO, Feb. 26, 2019 /PRNewswire/ — Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet…

Source: FDA New Drug Approvals